Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients.

Next Previous
Trial Profile

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Diabetes mellitus; Hyperlipidaemia; Hypertension; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms METATEL

Most Recent Events

  • 29 Aug 2011 Results published in the Hypertension.
  • 14 Jul 2010 Actual number of patients (56) added as reported by ClinicalTrials.gov.
  • 12 Jul 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top